The relative risk is incredibly small, since the base was small. I would say for many people the systemic benefits far outweigh the risk, especially if someone is morbidly obese.
Don't you mean absolute risk? The relative risk doubled, the absolute risk is small.
Just as you Adam predict AI has problems as well as good I believe long term more and more problems and health concerns with emerge from GPL1 drugs. Yes they may help type II diabetics more then hurt but for the general population who take it to be stick figures watch out for those long term effects. You are changing basic function of the GI system " GLP-1, leading to increased insulin secretion, reduced glucagon secretion, delayed gastric emptying, and appetite suppression, thereby improving glycemic control and promoting weight loss."
Yup, both are still low, relative to the effects of morbid obesity. Which is what these drugs really should be used for.
Yet obesity is behind most of the health issues we face as a nation, so obese patients will probably still come out ahead.
Err even with the cost reductions Trump just put in most people who are obese still can't afford it especially if they are presumably on other meds which I would suspect
